Atorvastatin does not affect the pharmacokinetics of cyclosporine in renal transplant recipients

European Journal of Clinical Pharmacology

Volumn 61, Issue 1, 2005, Pages 59-62

  Hermann, Monica ^a   Åsberg, Anders ^a,b   Christensen, Hege ^a   Reubsaet, Jan Leo Egge ^a   Holdaas, Hallvard ^b   Hartmann, Anders ^b  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

AM 9; ATORVASTATIN; CYCLOSPORIN A; CYTOCHROME P450 3A4; DRUG METABOLITE; ETHYLPHOSPHONOTHIOIC ACID S DIETHYLAMINOETHYL O ETHYL ESTER; PREDNISONE; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CHROMATOGRAPHY; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; PRIORITY JOURNAL; RECIPIENT; STATISTICAL SIGNIFICANCE; SURGICAL PATIENT;

ANTICHOLESTEREMIC AGENTS; AREA UNDER CURVE; CYCLOSPORINE; DRUG INTERACTIONS; HALF-LIFE; HEPTANOIC ACIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LINEAR MODELS; PYRROLES;

EID: 17644367866     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-004-0874-5     Document Type: Article

References (16)

1. Asberg A (2003) Interactions between cyclosporin and lipid-lowering drugs: implications for organ transplant recipients. Drugs 63:367-378
2. Asberg A, Hartmann A, Fjeldså E, Bergan S, Holdaas H (2001) Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients. Am J Transplant 382-386
3. Gomez DY, Wacher VJ, Tomlanovich SJ, Hebert MF, Benet LZ (1995) The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther 58:15-19
4. Hermann M, Asberg A, Christensen H, Holdaas H, Hartmann A, Reubsaet JL (2004) Substantially elevated levels of atorvastatin and metabolites in cyclosporine-treated renal transplant recipients. Clin Pharmacol Ther 76:388-391
5. Hermann M, Asberg A, Reubsaet JL, Sather S, Berg KJ, Christensen H (2002) Intake of grapefruit juice alters the metabolic pattern of cyclosporin A in renal transplant recipients. Int J Clin Pharmacol Ther 40:451-456
6. Hermann M, Christensen H, Reubsaet JL (2002) Evaluation of essential parameters in the chromatographic determination of cyclosporin A and metabolites using a D-optimal design. J Pharm Biomed Anal 30:1263-1276
7. Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang WP, Kirchgessner TG (1999) A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem 274:37161-37168
8. Kantola T, Kivisto K, Neuvonen P (1998) Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther 64:58-65
9. Mahalati K, Belitsky P, Sketris I, West K, Panek R (1999) Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. Transplantation 68:55-62
10. Omar MA, Wilson JP (2002) FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother 36:288-295
11. Renders L, Mayer-Kadner I, Koch C, Scharffe S, Burkhardt K, Veelken R, Schmieder RE, Hauser IA (2001) Efficacy and drug interactions of the new HMG-CoA reductase inhibitors cerivastatin and atorvastatin in CsA-treated renal transplant recipients. Nephrol Dial Transplant 16:141-146
12. Romero R, Calvino J, Rodriguez J, Sanchez-Guisande D (2000) Short-term effect of atorvastatin in hypercholesterolaemic renal-transplant patients unresponsive to other statins. Nephrol Dial Transplant 15:1446-1449
13. Steinijans VW, Hartmann M, Huber R, Radtke HW (1991) Lack of pharmacokinetic interaction as an equivalence problem. Int J Clin Pharmacol Ther Toxicol 29:323-328
14. Taylor PJ, Kubler PA, Lynch SV, Allen J, Butler M, Pillans PI (2004) Effect of atorvastatin on cyclosporine pharmacokinetics in liver transplant recipients. Ann Pharmacother 38:205-208. Epub 2003 Dec 2019
15. Winkler M, Schumann G, Petersen D, Oellerich M, Wonigeit K (1992) Monoclonal fluorescence polarization immunoassay evaluated for monitoring cyclosporine in whole blood after kidney, heart and liver transplantation. Clin Chem 38:123-126
16. Wu X, Whitfield LR, Stewart BH (2000) Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter. Pharm Res 17:209-215